RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Th17 lymphocytes are expandend in multiple sclerosis and are inhibited by interferon beta
2009-01-01 Novelli. F; Conti L.; Boselli D; Rolla S.; Clerico M.; Contessa G; Durelli L.
Th17, an effector T Lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon beta
2009-01-01 Luca Durelli; Simona Rolla; Marinella Clerico; Laura Conti; Giulia Contessa; paolo Ripellino; Delon La Puma; Emanuela Viglietta; Antonio Uccelli; mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; daniela Boselli; Francesco Novelli
The autoimmunity profile in interferon beta (AUPRIN) study: occurrence of autoimmune events during treatment with two different dosages of subcutaneous interferon beta–1a (REBIF)
2006-01-01 L. DURELLI; P. BARBERO; M. CLERICO; G. CONTESSA; A. PIPIERI; L. GIORDANO; FOR THE AUPRIN STUDY GROUP
The best indication to early treat the clinically isolated syndrome based on the clinical onset. A Cochrane analysis
2009-01-01 Clerico, M; Versino, E; Contessa, G; Ripellino, P; Palace, J; Tintore, M; Durelli, L
The independent comparison of interferon (incomin) trial: correlation of neutralising antibodies anti-interferon beta with clinical response and mri activity
2003-01-01 P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI
The optims study. I looking for a treatment response marker
2005-01-01 L. DURELLI; E. VERDUN; P. BARBERO; M. CLERICO; B. FERRERO; E. VERSINO; G. GIULIANI; E. MONTANARI; THE OPTIMS STUDY GROUP
The optims trial: the first prospective long term predictivity analysis trial of a treatment response marker to immunomodulatory drug in ms.
2005-01-01 L. DURELLI; P. BARBERO; M. CLERICO; A. RICCI; B. FERRERO; G. CONTESSA; E. VERSINO; G. GIULIANI; E. MONTANARI; AND THE OPTIMS STUDY GROUP; ITALY
To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
2009-01-01 Marinella Clerico; Fabrizio Faggiano; jacqueline Palace; Mar Tintore'; Luca Durelli
To evaluate anti-interferon (ifn) neutralizing antibody (nab) in relapsing remitting (rr) ms patients treated over the long term with an ifn beta-1b dose higher than that currently approved.
2005-01-01 A. RICCI; P. BARBERO; A PIPIERI; B. FERRERO; M. CUCCI; M. CLERICO; G. CONTESSA; L. GIORDANO; L. DURELLI; AND THE OPTIMS STUDY GROUP
To prevent conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane Metanalysis
2008-01-01 Marinella Clerico; Fabrizio Faggiano; Jacqueline palace; George Rice; Mar Tintore'; Luca Durelli
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 04-CONTRIBUTO IN ATTI DI CONVEGNO 109
- 04-CONTRIBUTO IN ATTI DI CONVEGNO... 109
Data di pubblicazione
- 2010 - 2017 24
- 2003 - 2009 85
Editore
- Springer-Verlag 36
- Lippincot Williams and Wilkins 12
- Antonio Federico 7
- SAGE publications 7
- Robert A. Gross 6
- SAGE Pubblications 5
- Lippincott Williams and Wilkins 4
- SAGE Publications 4
- Springer 4
- Springer Verlag-Italia 3
Rivista
- JOURNAL OF NEUROLOGY 2
Keyword
- Active learning 1
- Cooperative learning 1
- Flipped classroom 1
- Global education 1
- Global university 1
- INTERFERONI 1
- SCLEROSI MULTIPLA 1
- Student centered teaching methods 1
- TH17 1
- TH22 1
Lingua
- eng 109
Accesso al fulltext
- no fulltext 107
- open 2